BR0210905A - Anticorpos especìficos para cd44v6 - Google Patents
Anticorpos especìficos para cd44v6Info
- Publication number
- BR0210905A BR0210905A BR0210905-0A BR0210905A BR0210905A BR 0210905 A BR0210905 A BR 0210905A BR 0210905 A BR0210905 A BR 0210905A BR 0210905 A BR0210905 A BR 0210905A
- Authority
- BR
- Brazil
- Prior art keywords
- relates
- cd44v6
- specific antibodies
- antibody
- antibody proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 101150017002 CD44 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
"ANTICORPOS ESPECìFICOS PARA CD44V6". A presente invenção refere-se ao campo da oncologia. A invenção refere-se a anticorpos com seq³ência especificada, que são específicos para um epítopo que é codificado pela variante éxon v6 do gene CD44 e a derivados do referido anticorpo. A invenção também provê moléculas de ácido nucléico codificando as referidas proteínas de anticorpo. A invenção, além disso, refere-se aos métodos para produzir as referidas proteínas de anticorpo. A invenção também provê composições farmacêuticas compreendendo as referidas proteínas de anticorpo. A invenção, além disso, refere-se ao uso na fabricação de um medicamento para o tratamento de câncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01112237 | 2001-05-18 | ||
| US32514701P | 2001-09-26 | 2001-09-26 | |
| PCT/EP2002/005467 WO2002094879A1 (en) | 2001-05-18 | 2002-05-17 | Antibodies specific for cd44v6 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0210905A true BR0210905A (pt) | 2004-06-08 |
Family
ID=33442672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0210905-0A Expired - Fee Related BR0210905A (pt) | 2001-05-18 | 2002-05-17 | Anticorpos especìficos para cd44v6 |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1397387A1 (pt) |
| JP (1) | JP2005504517A (pt) |
| CN (1) | CN1541226A (pt) |
| AR (1) | AR036154A1 (pt) |
| BR (1) | BR0210905A (pt) |
| CA (1) | CA2443437A1 (pt) |
| CZ (1) | CZ20033476A3 (pt) |
| EA (1) | EA200301169A1 (pt) |
| EC (1) | ECSP034838A (pt) |
| EE (1) | EE200300569A (pt) |
| HU (1) | HUP0400030A3 (pt) |
| MX (1) | MXPA03010523A (pt) |
| PE (1) | PE20021098A1 (pt) |
| PL (1) | PL365735A1 (pt) |
| SK (1) | SK15592003A3 (pt) |
| WO (1) | WO2002094879A1 (pt) |
| YU (1) | YU91403A (pt) |
| ZA (1) | ZA200307365B (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071072B2 (en) | 1999-10-08 | 2011-12-06 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US7189397B2 (en) * | 1999-10-08 | 2007-03-13 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US7947496B2 (en) | 1999-10-08 | 2011-05-24 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US20050100542A1 (en) | 1999-10-08 | 2005-05-12 | Young David S. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US8048416B2 (en) | 1999-10-08 | 2011-11-01 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| JP4805848B2 (ja) | 2004-02-12 | 2011-11-02 | モルフォテック、インク． | 腫瘍抗原の生物活性を特異的に阻止するモノクローナル抗体 |
| ES2429340T3 (es) | 2005-03-10 | 2013-11-14 | Morphotek, Inc. | Anticuerpos anti-mesotelina |
| WO2006116592A2 (en) | 2005-04-22 | 2006-11-02 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| EA022911B1 (ru) * | 2007-06-13 | 2016-03-31 | Займодженетикс, Инк. | Способ лечения пациента, страдающего i или ii стадией системной красной волчанки |
| EP2009028A1 (en) * | 2007-06-27 | 2008-12-31 | Monoclonal Antibodies Therapeutics | Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors |
| CN102741292B (zh) | 2010-02-04 | 2015-10-21 | 霍夫曼-拉罗奇有限公司 | 在治疗头和颈鳞状细胞癌中使用的cd44单克隆抗体 |
| CN102337298B (zh) * | 2011-08-19 | 2013-11-06 | 黄开红 | 一种输送siRNA的免疫纳米载体及其制备方法和应用 |
| WO2013083497A1 (en) | 2011-12-06 | 2013-06-13 | F. Hoffmann-La Roche Ag | Antibody formulation |
| WO2017215637A1 (zh) * | 2016-06-15 | 2017-12-21 | 李翀 | 一种人子宫内膜癌的标志物、抗体及其应用 |
| CN107556388A (zh) * | 2016-06-30 | 2018-01-09 | 中国科学院深圳先进技术研究院 | 抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用 |
| JP2024512324A (ja) * | 2021-03-05 | 2024-03-19 | ジーオー セラピューティクス，インコーポレイテッド | 抗グリコｃｄ４４抗体およびその使用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0438310A1 (en) * | 1990-01-19 | 1991-07-24 | Merck & Co. Inc. | Method for producing recombinant immunoglobuline |
| GB9020282D0 (en) * | 1990-09-17 | 1990-10-31 | Gorman Scott D | Altered antibodies and their preparation |
| JPH08506801A (ja) * | 1992-11-20 | 1996-07-23 | アイシス・イノベーション・リミテッド | Ｃｄ４４エキソン６に対応するペプチド、そのペプチドに特異的な抗体、および、腫瘍診断にそれらの抗体を使用する方法 |
| UA58482C2 (uk) * | 1994-06-08 | 2003-08-15 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти |
| UY24389A1 (es) * | 1995-12-06 | 2001-10-25 | Karlsruhe Forschzent | Composición farmacéutica para el tratamiento de carcinoma de epitelio plano |
-
2002
- 2002-05-17 PE PE2002000422A patent/PE20021098A1/es not_active Application Discontinuation
- 2002-05-17 SK SK1559-2003A patent/SK15592003A3/sk not_active Application Discontinuation
- 2002-05-17 CZ CZ20033476A patent/CZ20033476A3/cs unknown
- 2002-05-17 MX MXPA03010523A patent/MXPA03010523A/es unknown
- 2002-05-17 YU YU91403A patent/YU91403A/sh unknown
- 2002-05-17 CA CA002443437A patent/CA2443437A1/en not_active Abandoned
- 2002-05-17 BR BR0210905-0A patent/BR0210905A/pt not_active Expired - Fee Related
- 2002-05-17 PL PL02365735A patent/PL365735A1/xx not_active Application Discontinuation
- 2002-05-17 WO PCT/EP2002/005467 patent/WO2002094879A1/en not_active Application Discontinuation
- 2002-05-17 EP EP02735364A patent/EP1397387A1/en not_active Ceased
- 2002-05-17 HU HU0400030A patent/HUP0400030A3/hu unknown
- 2002-05-17 JP JP2002592353A patent/JP2005504517A/ja active Pending
- 2002-05-17 AR ARP020101830A patent/AR036154A1/es not_active Suspension/Interruption
- 2002-05-17 CN CNA028101561A patent/CN1541226A/zh active Pending
- 2002-05-17 EA EA200301169A patent/EA200301169A1/ru unknown
- 2002-05-17 EE EEP200300569A patent/EE200300569A/xx unknown
-
2003
- 2003-09-22 ZA ZA200307365A patent/ZA200307365B/xx unknown
- 2003-11-10 EC EC2003004838A patent/ECSP034838A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0400030A2 (hu) | 2004-04-28 |
| WO2002094879A1 (en) | 2002-11-28 |
| CN1541226A (zh) | 2004-10-27 |
| EA200301169A1 (ru) | 2004-06-24 |
| PE20021098A1 (es) | 2003-02-11 |
| SK15592003A3 (sk) | 2004-06-08 |
| CZ20033476A3 (cs) | 2004-05-12 |
| MXPA03010523A (es) | 2004-07-01 |
| AR036154A1 (es) | 2004-08-18 |
| JP2005504517A (ja) | 2005-02-17 |
| YU91403A (sh) | 2006-05-25 |
| CA2443437A1 (en) | 2002-11-28 |
| ECSP034838A (es) | 2003-12-24 |
| EP1397387A1 (en) | 2004-03-17 |
| ZA200307365B (en) | 2004-05-10 |
| HUP0400030A3 (en) | 2006-02-28 |
| PL365735A1 (en) | 2005-01-10 |
| EE200300569A (et) | 2004-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0210905A (pt) | Anticorpos especìficos para cd44v6 | |
| WO2007067730A3 (en) | Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use | |
| HRP20040712B1 (hr) | Anti-amiloidna beta antitijela i njihova uporaba | |
| BRPI0819909B8 (pt) | anticorpo sintético humano ou humanizado isolado ou um fragmento funcional do mesmo, fragmento funcional e composição farmacêutica | |
| EA202092735A1 (ru) | Антагонизирующее cd73 антитело | |
| BR0211630A (pt) | Anticorpo, ácido nucleico isolado, vetores de expressão recombinantes, composição farmacêutica, método de inibição da atividade de tnfsf13b em um indivìduo sofrendo de um distúrbio no qual a atividade de tnfsf13b é prejudicial, uso do dito anticorpo, e, artigo de manufatura | |
| WO2007067992A3 (en) | Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 | |
| WO2008067283A3 (en) | Ovr110 antibody compositions and methods of use | |
| BR112012024964A2 (pt) | anticorpo de cadeia única bioespecífico psmaxcd3 de espécies cruzadas específicas, seu processso de preparação, seu uso, vetor, composição farmacêutica e kit | |
| SG170080A1 (en) | Human monoclonal antibodies to o8e | |
| BR0208396A (pt) | Ureìa de éster vinìlico | |
| HRP20080028A2 (en) | Cd19 antibodies and their uses | |
| WO2011069992A3 (en) | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target | |
| NZ543467A (en) | The severe acute respiratory syndrome coronavirus | |
| WO2006076691A3 (en) | Irta-2 antibodies and their uses | |
| BR0113921A (pt) | ácidos nucléicos e polipeptìdeos receptores | |
| WO2005097185A3 (en) | Irta-5 antibodies and their uses | |
| BR112012013915A2 (pt) | anticorpos anti-c4. 4a e usos dos mesmos | |
| MY150246A (en) | Alpha 5 - beta 1 antibodies and their uses | |
| BR0306878A (pt) | Peptìdeo não-agonista do receptor de fator de liberação de corticotropina 2, ácido nucleico e anticorpo isolados, composição farmacêutica e kit compreendendo o referido peptìdeo e uso do referido peptìdeo e ácido nucleico na fabricação de um medicamento | |
| BR0116763A (pt) | Anticorpos humanos especìficos para terapia seletiva do c ncer | |
| BRPI0407031A (pt) | Composições e métodos para tratamento de câncer empregando igsf9 e liv-1 | |
| WO2003105773A3 (en) | MUTATIONS OF PDGFRA ACTIVATED AS DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS | |
| BRPI0411800A (pt) | candidatos a fármacos e métodos para sua preparação | |
| BR0213779A (pt) | Molécula de ácido nucleico isolada, vetor, célula hospedeira, e, método para a preparação de um composto de quìmica fina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A,6A,7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010. |
|
| B15K | Others concerning applications: alteration of classification |
Ipc: C07K 16/28 (2006.01), A61K 39/00 (2006.01), A61P 3 |